Home › Trials › NCT03773965

Evaluating baricitinib for treating juvenile idiopathic arthritis in children

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)

Phase 3 Interventional Eli Lilly and Company · NCT03773965

This study tests if continuing treatment with baricitinib helps children with juvenile idiopathic arthritis feel better and stay safe.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment190 (estimated)
Ages1 Year to 18 Years
SexAll
SponsorEli Lilly and Company Industry-sponsored
Drugs / interventionsbaricitinib
Locations80 sites (Rosario and 79 other locations)
Trial IDNCT03773965 on ClinicalTrials.gov

What this trial studies

This study investigates the safety and effectiveness of baricitinib in children aged 1 to less than 18 years who have juvenile idiopathic arthritis (JIA). Participants must have previously completed a study involving baricitinib and cannot have had a permanent discontinuation of the drug. The study aims to build on prior findings to determine if continued treatment is beneficial for this age group. The focus is on various forms of JIA, including polyarticular and systemic types.

Who should consider this trial

Good fit: Ideal candidates are children aged 1 to less than 18 years who have previously participated in baricitinib studies for JIA.

Not a fit: Patients who have had a permanent discontinuation of baricitinib or developed an allergy to it will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new effective treatment option for children suffering from juvenile idiopathic arthritis.

How similar studies have performed: Previous studies involving baricitinib for JIA have shown promising results, indicating potential success for this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participants must have completed a previous study of baricitinib for the treatment of JIA.

Exclusion Criteria:

* Participants must not have had a permanent discontinuation of baricitinib in the prior study.
* Participants must have not developed an allergy to baricitinib.

Where this trial is running

Rosario and 79 other locations

+30 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Juvenile Idiopathic ArthritisPolyarticular JIAOligoarthritisJuvenile psoriatic arthritisEnthesitis-related juvenile idiopathic arthritisSystemic JIA with and without systemic features
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.